After 1- and 6-Month Gains, Gene Editing Companies Await Q3 Results
As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in…
Reporter’s Notebook: The Overdue Breakout for Gene Therapy and Gene Editing
As gene editing enters a new era, leaders discuss Baby KJ’s implications for families, science, and industry. (Left…
Prime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD Data
Prime Medicine Inc. (NASDAQ:PRME) is one of the best hot stocks to buy according to Wall Street analysts.…